vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $5.5M, roughly 1.7× Taysha Gene Therapies, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -507.8%, a 535.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 33.8%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 23.8%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
ECBK vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $5.5M |
| Net Profit | $2.6M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | -516.0% |
| Net Margin | 27.3% | -507.8% |
| Revenue YoY | 33.8% | 171.3% |
| Net Profit YoY | 79.5% | -48.3% |
| EPS (diluted) | $0.32 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $5.5M | ||
| Q3 25 | $8.8M | $0 | ||
| Q2 25 | $8.0M | $2.0M | ||
| Q1 25 | $6.9M | $2.3M | ||
| Q4 24 | $7.1M | $2.0M | ||
| Q3 24 | $6.6M | $1.8M | ||
| Q2 24 | $6.3M | $1.1M | ||
| Q1 24 | $6.2M | $3.4M |
| Q4 25 | $2.6M | $-27.9M | ||
| Q3 25 | $2.4M | $-32.7M | ||
| Q2 25 | $1.4M | $-26.9M | ||
| Q1 25 | $1.3M | $-21.5M | ||
| Q4 24 | $1.4M | $-18.8M | ||
| Q3 24 | $1.1M | $-25.5M | ||
| Q2 24 | $791.0K | $-20.9M | ||
| Q1 24 | $621.0K | $-24.1M |
| Q4 25 | 36.7% | -516.0% | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 23.9% | -1347.1% | ||
| Q1 25 | 24.9% | -930.5% | ||
| Q4 24 | 27.3% | -985.8% | ||
| Q3 24 | 23.3% | -1448.4% | ||
| Q2 24 | 16.9% | -1915.4% | ||
| Q1 24 | 13.4% | -713.3% |
| Q4 25 | 27.3% | -507.8% | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 18.0% | -1353.6% | ||
| Q1 25 | 18.7% | -935.2% | ||
| Q4 24 | 20.3% | -929.0% | ||
| Q3 24 | 17.2% | -1427.5% | ||
| Q2 24 | 12.6% | -1882.0% | ||
| Q1 24 | 10.0% | -705.4% |
| Q4 25 | $0.32 | $-0.08 | ||
| Q3 25 | $0.29 | $-0.09 | ||
| Q2 25 | $0.17 | $-0.09 | ||
| Q1 25 | $0.16 | $-0.08 | ||
| Q4 24 | $0.18 | $-0.07 | ||
| Q3 24 | $0.14 | $-0.10 | ||
| Q2 24 | $0.09 | $-0.09 | ||
| Q1 24 | $0.07 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $246.9M |
| Total Assets | $1.6B | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $319.8M | ||
| Q3 25 | $201.9M | $297.3M | ||
| Q2 25 | $191.0M | $312.8M | ||
| Q1 25 | $143.7M | $116.6M | ||
| Q4 24 | $309.4M | $139.0M | ||
| Q3 24 | $114.8M | $157.7M | ||
| Q2 24 | $108.7M | $172.7M | ||
| Q1 24 | $109.8M | $124.0M |
| Q4 25 | $171.9M | $246.9M | ||
| Q3 25 | $169.3M | $219.0M | ||
| Q2 25 | $168.3M | $248.7M | ||
| Q1 25 | $168.6M | $55.1M | ||
| Q4 24 | $168.3M | $71.5M | ||
| Q3 24 | $166.0M | $88.8M | ||
| Q2 24 | $166.5M | $108.9M | ||
| Q1 24 | $165.8M | $53.8M |
| Q4 25 | $1.6B | $343.3M | ||
| Q3 25 | $1.6B | $316.6M | ||
| Q2 25 | $1.5B | $333.3M | ||
| Q1 25 | $1.5B | $138.4M | ||
| Q4 24 | $1.4B | $160.4M | ||
| Q3 24 | $1.4B | $180.2M | ||
| Q2 24 | $1.3B | $200.4M | ||
| Q1 24 | $1.3B | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-26.7M |
| Free Cash FlowOCF − Capex | $9.0M | — |
| FCF MarginFCF / Revenue | 94.7% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-26.7M | ||
| Q3 25 | $4.0M | $-24.2M | ||
| Q2 25 | $1.9M | $-20.2M | ||
| Q1 25 | $-631.0K | $-22.0M | ||
| Q4 24 | $6.2M | $-18.3M | ||
| Q3 24 | $861.0K | $-21.6M | ||
| Q2 24 | $1.4M | $-21.5M | ||
| Q1 24 | $-429.0K | $-19.8M |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | $-24.3M | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-649.0K | — | ||
| Q4 24 | $6.2M | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | $1.3M | $-21.7M | ||
| Q1 24 | $-449.0K | $-19.9M |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -9.4% | — | ||
| Q4 24 | 86.8% | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | 21.4% | -1951.9% | ||
| Q1 24 | -7.2% | -584.5% |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | 0.1% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | 0.6% | 18.1% | ||
| Q1 24 | 0.3% | 4.1% |
| Q4 25 | 3.55× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
